Relationship between peroxisome proliferator-activated receptor α and neutrophils in COPD Source: Eur Respir J 2004; 24: Suppl. 48, 452s Year: 2004
The effect of peroxisome proliferator-activated receptor-? ligands on in vitro and in vivo models of COPD Source: Eur Respir J 2014; 43: 409-420 Year: 2013
Peroxisome proliferator-activated receptor expression is reduced in skeletal muscle in COPD Source: Eur Respir J 2007; 30: 245-252 Year: 2007
Activation of airway epithelial cell inhibited by peroxisome proliferator-activated receptor γ Source: Eur Respir J 2006; 28: Suppl. 50, 229s Year: 2006
The effects of exercise training on peroxisome proliferator-activated receptor (PPAR) expression in skeletal muscle in COPD Source: Annual Congress 2009 - Emerging physiology behind pulmonary rehabilitation Year: 2009
Peroxisome proliferator-activated receptor γ inhibits acrolein-induced airway mucus hypersecretion in rats Source: Annual Congress 2008 - Inflammatory trigger mechanisms in asthma and COPD Year: 2008
Peroxisome proliferator-activated receptor gamma antagonist, GW9662, inhibits microparticles generation by calcium ionophore-stimulated monocytes/macrophages Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD Year: 2008
The role of peroxisome proliferator-activated receptor γ in pulmonary hypertension Source: Annual Congress 2009 - Pulmonary circulation II Year: 2009
Impacts of peroxisome proliferator-activated receptor gamma activation on cigarette smoke-induced exacerbated response to bacteria Source: Eur Respir J 2015; 45: 191-200 Year: 2015
The relationship of peroxisome proliferator activated receptor γ ligands and IL-6 in sepsis of rats Source: Annual Congress 2009 - Acute lung injury and biomarkers Year: 2009
Role of peroxisome proliferator activated receptor γ in COPD Source: Annual Congress 2009 - Airway inflammation and host defence Year: 2009
Peroxisome proliferator activated receptor gamma (PPARγ) agonist rosiglitizone inhibits upregulation of mucin gene expression in two airway epithelial cell lines Source: Eur Respir J 2005; 26: Suppl. 49, 97s Year: 2005
Peroxisome proliferator-activated receptors: a therapeutic target in COPD? Source: Eur Respir J 2008; 31: 502-508 Year: 2008
PPAR-γ agonists as therapy for diseases involving airway neutrophilia Source: Eur Respir J 2004; 24: 18-23 Year: 2004
Effects of peroxisome proliferators-activated receptor-α, γ agonists on acute lung injury rats induced by lipopolysaccharide Source: Eur Respir J 2006; 28: Suppl. 50, 397s Year: 2006
Role of exogenous ligands for the peroxisome proliferator-activated receptor-β/δ in the development of bleomycin-induced lung injury Source: Annual Congress 2010 - Cell biology and immunology of lung disease Year: 2010
Diminished peroxisome proliferator-activated receptor (PPAR) regulation as a potential mechanism for the persistent inflammation in chronic obstructive pulmonary disease Source: Eur Respir Rev 2006; 15: 211-212 Year: 2006
Diminished peroxisome proliferator-activated receptor (PPAR) regulation as a potential mechanism for the persistent inflammation in chronic obstructive pulmonary disease Source: Eur Respir J 2006; 28: Suppl. 50, 856s Year: 2006
Peroxisome proliferator-activated receptor gamma (PPARγ) protects against pulmonary arterial hypertension (PAH) Source: Eur Respir J 2007; 30: Suppl. 51, 6s Year: 2007
PKA/cAMP-independent transactivation of glucocorticoid receptor by long acting β2 agonists Source: Eur Respir J 2006; 28: Suppl. 50, 103s Year: 2006